肿瘤治疗电场相关皮肤毒性:基于病例的综述
肿瘤治疗电场(TTFields)已获FDA批准用于复发性胶质母细胞瘤,III期试验显示与替莫唑胺联用可改善生存。皮肤不良反应最常见,本综述通过代表性病例介绍其表现、处理和转归,强调预防性患者与操作者教育可减少多数皮肤事件,与贝伐珠单抗等联用时的皮肤毒性尚不明确,需密切随访。
要点
- TTFields最常见不良反应为皮肤毒性,头痛发生率在两组中相同。
- 通过患者和操作者教育等预防策略可减少多数皮肤不良事件。
- TTFields与贝伐珠单抗等联用时的皮肤毒性未知,需密切随访。
核心结论
- 预防性告知和教育患者及操作者可以预防许多皮肤不良事件。
- TTFields与贝伐珠单抗等其他疗法联用时的皮肤毒性尚不明确,需要密切随访。
研究设计与样本
- 基于病例的综述,描述使用TTFields的代表性患者的表现、治疗和转归。
主要发现
- 皮肤不良反应是最常见的不良事件,头痛是第二常见不良事件,在复发性胶质母细胞瘤III期注册试验中两组头痛发生率相同。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The novel anti-mitotic based tumor treating fields (TTFields) is FDA approved for recurrent glioblastoma. Recently the phase III upfront trial combining the Novo TTF-100A device, called Optune, with temozolomide following concurrent radiation therapy and chemotherapy, demonstrated improvement in survival. Wider use of this novel therapy is expected. The most common adverse event is dermatologic, which dominates compared to the next most frequently observed adverse event of headaches, the incidence of which was even in both arms in the phase III registration trial for recurrent glioblastoma. Our case review outlines the presentation, treatment, and outcome of representative patients using TTFields. In summary, preventative strategies to inform and educate patients and operators can prevent many of these dermatological events. Skin toxicity in the setting of concurrent use of TTFields with other therapies such as bevacizumab is an unknown and will need to be closely followed.
引用
- Lukas RV, Ratermann KL, Wong ET, et al. Skin toxicities associated with tumor treating fields: case based review. J Neurooncol. 2017. PMID: 28849343. doi:10.1007/s11060-017-2612-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。